Sentences with phrase «number of new product introductions»

Drew Clark: Resco has had an amazing start to the year with a number of new product introductions.

Gluten - free products have been witnessing strong growth even among non-celiac patients with more number of new product introductions in snacks and alcoholic beverages.

Not exact matches

Certain matters discussed in this news release are forward - looking statements that involve a number of risks and uncertainties including, but not limited to, doubts about the Company's ability to continue as a going concern, the need to obtain additional funding, risks in product development plans and schedules, rapid technological change, changes and delays in product approval and introduction, customer acceptance of new products, the impact of competitive products and pricing, market acceptance, the lengthy sales cycle, proprietary rights of the Company and its competitors, risk of operations in Israel, government regulations, dependence on third parties to manufacture products, general economic conditions and other risk factors detailed in the Company's filings with the United States Securities and Exchange Commission.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

According to Innova Market Research's latest Global New Product Introductions Report, almonds are now the number one nut in new introductions in Europe with a 48 % regional share and a new record high of 42 % globalNew Product Introductions Report, almonds are now the number one nut in new introductions in Europe with a 48 % regional share and a new record high of 4Introductions Report, almonds are now the number one nut in new introductions in Europe with a 48 % regional share and a new record high of 42 % globalnew introductions in Europe with a 48 % regional share and a new record high of 4introductions in Europe with a 48 % regional share and a new record high of 42 % globalnew record high of 42 % globally.

And while Chicago can't match Detroit in the total number of new model introductions, plenty of manufacturers save their products for Chicago, knowing that while they may get lost at the Detroit show, they'll get good billing in Chicago.

Building on the recent introduction of the all - new Infiniti JX 7 - passenger luxury crossover, the Infiniti lineup enters the 2013 model year with a number of key product enhancements — led by the addition of standard 3.7 - liter V6 engines for the Infiniti EX and V6 versions of the Infiniti FX.

«With the introduction of SLP's all - new 2010 Full - Line Catalog, featuring a significant number of new products for the new Camaro, Mustang and Challenger, displaying in this year's SEMA Show makes a lot of sense for SLP.»

Not surprisingly, GfK also reports that the number or grain - free pet products on the market increased 33 percent — accounting for approximately one - third of all new pet product introductions — during the same period.